



Life-changing
science

PYC Shareholder Update

3Q 2022

The purpose of this presentation is to provide an update of the business of PYC Therapeutics Limited (ASX:PYC) ['PYC']. These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by PYC and should not be relied upon as an independent source of information. Please contact PYC and/or refer to the Company's website for further information.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information.

Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside PYC's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and PYC's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution.

This presentation should not be relied on as a recommendation or forecast by PYC. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.



A brief re-cap of the PYC story



3 primary messages for today:

- **Strong macro trends:** RNA therapeutics are having a major impact and this will continue
- **PYC is delivering** on its clinical transformation (integrated discovery and development capability position PYC to capitalise on this trend)
- Immediate focus on **value recognition**



Q&A

A precision medicine (RNA) company positioned for growth



Scalability



A platform technology

A precision medicine platform in the era of precision medicines

Multiple assets



With multiple programs progressing into the clinic

Initial focus on blinding eye diseases with central nervous system and kidney close behind

Genetic medicines



Targets with human genetic evidence are more likely to succeed in the clinic ¹ ²

PYC progressing lead program to an IND in Q4 and an anticipated clinical trial in early 2023

1) Nelson, M., Tipney, H., Painter, J. et al. The support of human genetic evidence for approved drug indications. Nat Genet 47, 856–860 (2015)
2) Szustakowski, J.D., Balasubramanian, S., Kvikstad, E. et al. Advancing human genetics research and drug discovery through exome sequencing of the UK Biobank. Nat Genet 53, 942–948 (2021). <https://doi.org/10.1038/s41588-021-00885-0> pre-print version at <https://doi.org/10.1101/2020.11.02.20222232>

The trend towards RNA therapeutics is here and here to stay



John Maraganore 🇺🇦 🇺🇦 @JMar... · 10h
 I see this exact same story playing out with RNA-based medicines, led by ASO and siRNA. Very exciting for patients, innovation, and science!



Paras Sharma @paras_biot... · 10h
 Disruptive Innovation takes time to inflect
 (as presented by mAb dev path)



July 20, 2022 06:00 AM EDT Updated 09:39 AM | Financing



With a fresh \$100M in hand, one RNA startup is moving to the clinic, finding partners and building a new lab — all at once

August 16, 2022 06:45 AM EDT Updated 10:36 AM | Deals



UPDATED: 'We have failed to fail': Merck gambles \$250M cash on a next-gen approach to mRNA — after punting its big alliance with Moderna

PHARMA, BIOPHARMA

Alnylam drug succeeds in heart study, setting stage for FDA filing and showdown with Pfizer

PYC is set to become a clinical-stage company with the progression of the RP11 program into a combined phase 1/2 study in 1H 2023



RP11 is well progressed through non-clinical testing and is on track to enter phase 1/2 clinical trials in human patients in 1H 2023

Achievements to date



Anticipated major milestones in next 15 months ¹



*NHP – Non-Human Primate.

[^] Single Ascending Dose study in humans

1. Management's current estimate on timing of upcoming major milestones.